Tyra Biosciences Appoints New CMO, Adds Directors

Ticker: TYRA · Form: 8-K · Filed: Oct 25, 2024 · CIK: 1863127

Tyra Biosciences, Inc. 8-K Filing Summary
FieldDetail
CompanyTyra Biosciences, Inc. (TYRA)
Form Type8-K
Filed DateOct 25, 2024
Risk Levelmedium
Pages5
Reading Time6 min
Key Dollar Amounts$0.0001
Sentimentneutral

Sentiment: neutral

Topics: executive-changes, board-appointments, personnel

TL;DR

Tyra Biosciences beefs up exec team with new CMO and board members.

AI Summary

Tyra Biosciences, Inc. announced on October 24, 2024, a series of significant executive and board changes. These include the appointment of Dr. Todd W. P. Bracher as Chief Medical Officer, and the election of Dr. Bracher and Ms. Sarah E. Kelly to the Board of Directors. The company also disclosed compensatory arrangements for these individuals.

Why It Matters

These executive and board changes could signal a strategic shift or a strengthening of leadership for Tyra Biosciences as it advances its drug development pipeline.

Risk Assessment

Risk Level: medium — Executive and board changes can introduce uncertainty regarding future strategy and execution, impacting investor confidence.

Key Players & Entities

  • Tyra Biosciences, Inc. (company) — Registrant
  • Dr. Todd W. P. Bracher (person) — Appointed Chief Medical Officer and elected to Board of Directors
  • Ms. Sarah E. Kelly (person) — Elected to Board of Directors
  • October 24, 2024 (date) — Date of earliest event reported

FAQ

Who has been appointed as the new Chief Medical Officer of Tyra Biosciences?

Dr. Todd W. P. Bracher has been appointed as the new Chief Medical Officer.

When was the earliest event reported in this 8-K filing?

The earliest event reported was on October 24, 2024.

Who were elected to the Board of Directors of Tyra Biosciences?

Dr. Todd W. P. Bracher and Ms. Sarah E. Kelly were elected to the Board of Directors.

What is the principal executive office address for Tyra Biosciences?

The principal executive office is located at 2656 State Street, Carlsbad, California, 92008.

What is the IRS Employer Identification Number for Tyra Biosciences?

The IRS Employer Identification Number for Tyra Biosciences is 83-1476348.

Filing Stats: 1,557 words · 6 min read · ~5 pages · Grade level 14.9 · Accepted 2024-10-25 08:01:32

Key Financial Figures

  • $0.0001 — ich registered Common Stock, par value $0.0001 per share TYRA Nasdaq Global Select

Filing Documents

Forward-Looking Statements

Forward-Looking Statements Tyra cautions you that statements contained in this report regarding matters that are not historical facts are forward-looking statements. The forward-looking statements are based on our current beliefs and expectations and include, but are not limited to: the potential safety and therapeutic benefits of TYRA-300. Actual results may differ from those set forth in this report due to the risks and uncertainties inherent in our business, including, without limitation: interim results of a clinical trial are not necessarily indicative of final results and one or more of the clinical outcomes may materially change as patient enrollment continues, following more comprehensive reviews of the data, as follow-up on the outcome of any particular patient continues and as more patient or final data becomes available, including the risk that unconfirmed responses may not ultimately result in confirmed responses to treatment after follow-up evaluations; the potential for proof-of-concept results to fail to result in successful subsequent development of TYRA-300; we are early in our development efforts, have only recently begun testing TYRA-300 and TYRA-200 for oncology in clinical trials and the approach we are taking to discover and develop drugs based on our SNP platform is novel and unproven and it may never lead to product candidates that are successful in clinical development or approved products of commercial value; potential delays in the commencement, enrollment, data readouts and completion of preclinical studies and clinical trials; results from preclinical studies or early clinical trials not necessarily being predictive of future results; our dependence on third parties in connection with manufacturing, research and preclinical testing; acceptance by the FDA of INDs or of similar regulatory submissions by comparable foreign regulatory authorities for the conduct of clinical trials of TYRA-300 in pediatric achondroplasia and hypochondropl

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Slide Presentation 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. TYRA BIOSCIENCES, INC. Date: October 25, 2024 By: /s/ Ali Fawaz Ali Fawaz General Counsel and Secretary

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.